Incyte's atopical dermatitis cream delayed
The US FDA needs more time for its review of a new cream for the treatment of atopical dermatitis from the company Incyte. This delay could benefit Leo Pharma.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
It will be another three months before the US Food and Drug Administration (FDA) is ready to give its verdict on the drug ruxolitinib from Incyte. The review period for the drug ruxolitinib has been extended until Sept. 21, according a company press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Eli Lilly has to wait a while longer for FDA verdict
For subscribers
